

RECORDATI: DOCUMENTS RELATING TO THE ORDINARY GENERAL MEETING OF THE SHAREHOLDERS CALLED FOR 22.04.2024

Milan, 22nd March 2024 – Please be informed that the following reports approved by the Board of Directors of Recordati S.p.A. on 19th March 2024:

- (i) the Report on the 2024 Remuneration policy and the remuneration paid for 2023;
- (ii) the **Directors' Reports relating to the following items of the agenda of the Ordinary Shareholders' Meeting** called for the 22nd April 2024:
 - item no. 2 (<u>Report on the Remuneration policy and the remuneration paid</u>) which includes, as its annex, the Report on Remuneration policy and the remuneration paid referred to in point (i); and
 - item no. 3 (Authorization to the purchase and disposal of treasury stock),

are available to the public, as of today, at the Company's registered office and published on the Company's website (<u>www.recordati.it</u>, the first report in the Governance - Remuneration section; and the other reports in the Investors - Shareholder Information section) and on the '1INFO' storage mechanism (<u>www.1info.it</u>).

Recordati (Reuters RECI.MI, Bloomberg REC IM) is an international pharmaceutical group listed on the Italian Stock Exchange (ISIN IT 0003828271) uniquely structured to bring treatment across specialty and primary care, consumer healthcare, and rare diseases. We believe that health, and the opportunity to live life to the fullest, is a right, not a privilege. We want to support people in unlocking the full potential of their lives. We have fully integrated operations across research & development, chemical and finished product manufacturing through to commercialisation and licensing. Established in 1926, Recordati operates in approximately 150 countries across EMEA, Americas and APAC regions. At the end of 2023, Recordati employed over 4,450 people and consolidated revenue of \notin 2,082.3 million. For more information, please visit <u>www.recordati.com</u>

Investor Relations Eugenia Litz +44 7824 394 750 investorelations@recordati.it Investor Relations Lucia Abbatantuoni +39 337 1025645 investorelations@recordati.it Media Relations Brunswick: Barbara Scalchi / Andrea Mormandi +39 02 9288 6200 recordati@brunswickgroup.com

RECORDATI INDUSTRIA CHIMICA E FARMACEUTICA S.p.A.

 Registered office
 SHARE CAPITAL € 26,140,644.50 fully paid up

 VIA M. CIVITALI, 1
 SHARE CAPITAL € 26,140,644.50 fully paid up

 20148 MILAN, ITALY
 BUSINESS REGISTER OF MILAN, MONZA, BRIANZA and LODI

 TEL. +39 0248787.1
 00748210150

 FAX +39 0240073747
 TAX CODE/VAT NO. 00748210150

Company subject to management and coordination by Rossini Luxembourg S.àr.l